CYTOSORBENTS CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
CYTOSORBENTS CORPORATION (CTSO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $0.75 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2026-08-06
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2026-03-31 was $0.75, a 26.47% decline year-over-year.
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2025-03-31 was $1.02, a 60.47% decline year-over-year.
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2024-03-31 was $2.58, a 1.18% increase year-over-year.
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2023-03-31 was $2.55, a 36.41% decline year-over-year.
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2025 was $1.01, a 55.31% decline from fiscal 2024.
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2024 was $2.26, a 12.74% decline from fiscal 2023.
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2023 was $2.59, a 29.04% decline from fiscal 2022.
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2022 was $3.65, a 15.90% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.75 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $0.75 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $1.01 10-K · filed 2026-03-30 | |||
| 2025-09-30 | $1.55 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $0.80 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $1.02 10-Q · filed 2025-05-14 | |||
| 2024-12-31 | $2.26 10-K · filed 2026-03-30 | |||
| 2024-09-30 | $2.30 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $2.73 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $2.58 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $2.59 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $2.53 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $2.79 10-Q · filed 2023-08-01 | |||
| 2023-03-31 | $2.55 10-Q · filed 2023-05-02 | |||
| 2022-12-31 | $3.65 10-K · filed 2023-03-09 | |||
| 2022-09-30 | $3.74 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $4.29 10-Q · filed 2022-08-02 | |||
| 2022-03-31 | $4.01 10-Q · filed 2022-05-03 | |||
| 2021-12-31 | $4.34 10-K · filed 2022-03-10 | |||
| 2021-09-30 | $4.33 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $4.31 10-Q · filed 2021-08-03 | |||
| 2021-03-31 | $4.11 10-Q · filed 2021-05-04 | |||
| 2020-12-31 | $4.15 10-K · filed 2021-03-09 | |||
| 2020-09-30 | $4.26 10-Q · filed 2020-11-04 | |||
| 2020-06-30 | $4.17 10-Q · filed 2020-08-04 | |||
| 2020-03-31 | $4.14 10-Q · filed 2020-05-05 | |||
| 2019-12-31 | $4.47 10-K · filed 2020-03-05 | |||
| 2019-09-30 | $8.12 10-Q · filed 2019-11-05 | |||
| 2019-06-30 | $6.75 10-Q · filed 2019-08-06 | |||
| 2019-03-31 | $6.90 10-Q · filed 2019-05-07 | |||
| 2018-12-31 | $3.62 10-K · filed 2019-03-07 | |||
| 2018-09-30 | $3.41 10-Q · filed 2018-11-06 | |||
| 2018-06-30 | $3.39 10-Q · filed 2018-08-02 | |||
| 2018-03-31 | $3.43 10-Q · filed 2018-05-08 | |||
| 2017-12-31 | $2.38 10-K · filed 2018-03-08 | |||
| 2017-09-30 | $2.36 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | $2.33 10-Q · filed 2017-08-07 | |||
| 2017-03-31 | $2.29 10-Q · filed 2017-05-08 | |||
| 2016-12-31 | $1.13 10-K · filed 2017-03-03 | |||
| 2016-09-30 | $1.04 10-Q · filed 2016-11-07 | |||
| 2016-06-30 | $2.23 10-Q · filed 2016-08-09 | |||
| 2016-03-31 | $0.69 10-Q · filed 2016-05-09 | |||
| 2015-12-31 | $0.21 10-K · filed 2016-03-09 | |||
| 2015-09-30 | $0.13 10-Q · filed 2015-11-13 | |||
| 2015-06-30 | $0.06 10-Q · filed 2015-08-13 | |||
| 2015-03-31 | $0.06 10-Q · filed 2015-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |